Skip to content

The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections

The Impact of the Use of Chlorhexidine-Based Bathing System in the Hospital to Reduce the Incidence of MRSA/VRE Infection or Colonization and Nosocomial Bloodstream Infections (BSI)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00448942
Enrollment
5300
Registered
2007-03-19
Start date
2004-11-30
Completion date
2006-01-31
Last updated
2007-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRSA Colonization, MRSA Infection, Nosocomial Bacteremia, Nosocomial Fungemia, VRE Colonization, VRE Infection

Keywords

Staphylococcus aureus [B03.510.400.790.750.100], Enterococcus faecalis [B03.510.400.800.280.280], Enterococcus faecium [B03.510.400.800.280.300], Bacteremia [C01.252.100], Fungemia [C01.703.360], Infection Control [G03.850.780.200.450], Antisepsis [G03.850.780.200.450.150]

Brief summary

The purpose of this study was to determine if the use of daily chlorhexidine bathing would decrease the incidence of MRSA and VRE colonization and healthcare associated Bloodstream Infections (BSI) among Intensive Care Unit (ICU) patients.

Detailed description

Infections due to Staphylococci including MRSA are the predominant nosocomially acquired complication in the intensive care unit. The increasing incidence of MRSA colonization and infection among ICU patients has been attributed to many factors including increased admission of patients already colonized with MRSA to the ICU, poor compliance with handwashing and barrier precautions, delayed identification of MRSA colonized patients, and understaffing. Measures that have proven to limit horizontal transmission between patients and staff and staff to patients include strict attention to barrier precautions and handwashing. Unfortunately both of these strategies require levels of compliance that are often not achieved. Nosocomial blood stream infections are a leading source of morbidity and mortality among intensive care unit patients. Several modifiable factors have been shown to increase the risk of bloodstream infections. These include lapses in the use of strict sterile technique in the insertion of central venous catheters and improper site preparation. New CDC guidelines on the prevention of catheter related bloodstream infections recommend that the preferential use of chlorhexidine containing skin disinfectants be used for site preparation prior to insertion. The use of chlorhexidine reduces residual skin organisms as well as inhibits their rebound growth and has been demonstrated to reduce catheter-associated bloodstream infections in comparison to other skin disinfectant products such as povidone-iodine. As a result of guidelines promoting the use of chlorhexidine, a number of intensive care units have implemented quality improvement projects examining the potential role of chlorhexidine based bathing of intensive care unit patients in reducing nosocomial transmission of multiresisitant organisms such as MRSA and vancomycin-resistant enterocooci (VRE). The goal of the currently proposed study is to analyse existing data from participating intensive care units that have adopted the use of chlorhexidine antisepsis to determine the impact of chlorhexidine on bacterial colonization and nosocomial infections Participating hospitals who have completed quality improvement projects that included the use of chlorhexidine in bathing of ICU patients will submit de-identified data on nosocomial bacteremias and MRSA and VRE colonization during defined time periods where chlorhexidine bathing was used in comparison to time periods where regular bathing procedures were utilized.

Interventions

BEHAVIORALDaily bathing with Chlorhexidine based product

Sponsors

Weill Medical College of Cornell University
CollaboratorOTHER
Washington University School of Medicine
CollaboratorOTHER
Johns Hopkins University
CollaboratorOTHER
University of Tennessee
CollaboratorOTHER
Centers for Disease Control and Prevention
CollaboratorFED
Hunter Holmes Mcguire Veteran Affairs Medical Center
Lead SponsorFED

Study design

Observational model
DEFINED_POPULATION
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult patients admitted to study units

Exclusion criteria

* Children under the age of 18 * Previous adverse reaction or documented allergy to chlorhexidine based products

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026